Learn from the Leaders
Promedica International CMEOver the years, we at Promedica International CME have been privileged to work with the world’s leading physicians as Program Directors and Faculty to produce major educational activities to help improve the quality of healthcare you can offer your patients. Now we are delighted to add to your educational opportunities through this unique web blog entitled “Learn from the Leaders”. We hope you will appreciate the following opportunities:
- Learn about emerging techniques and technologies at an early stage, directly from the source.
- Share comments and ask questions in an informal environment
- Discover new ideas years before they can be published in the journals
- A forum for sharing tips and subtle nuances of techniques
Treating Hyperlipidemic Patients with PCSK9 Agents
Cardiovascular specialists have been excited about the clinical results coming in for many of our difficult to treat hyperlipidemic patients with the new PCSK9 agents. We will delve into an important discussion on the "PCSK9 Revolution" at the annual Cardiovascular...
Are We Doing Enough to Treat Hypertension?
Hypertension rates have been steadily growing for decades. Our health care system is now also facing an epidemic of CHF brought about by a number of factors, including untreated hypertension. As cardiologists, we see a critical opportunity aimed at addressing the...
New Treatments for CHF
Case Study: Your 80 year old patient with CHF is already on an ACE inhibitor, appropriate beta blocker, and a spironolactone inhibitor. He has a synchronized pacemaker and an ICD but still comes to the hospital with worsening symptoms every few months. How would you...
Lipid experts discuss PCSK9 Inhibitors at CDM 2015
Dr. Heuser is interested to hear what your approach would be with the following patient. Please comment below with your thoughts. You see a 50 year old gentleman with 3 vessel coronary disease. This non-diabetic, non-smoker really takes care of himself, but in spite...
Discussion on PCSK9 Inhibitors
A 65 year old asymptomatic woman sees you for therapy. She has a positive family history of early CV mortality. Her cholesterol is over 400 with intolerance to statins. She carries a diagnosis of homozygous familial hypercholesterolemia (HoFH). What is the role of the...
Case Study: Women & Heart Disease
The following case study will be referenced at the upcoming Cardiovascular Disease Management: A Case-Based Approach, 3rd Annual Symposium, which will take place October 1-2, 2015 at the historic Arizona Biltmore Hotel in Phoenix, Arizona. Dr. Heuser is interested in...
Case Study: Aortic Valve Disease
Dr. Rich Heuser's upcoming Cardiovascular Disease Management: A Case-Based Approach, 3rd Annual Symposium, will take place October 1-2, 2015 at the historic Arizona Biltmore Hotel in Phoenix, Arizona. The following case study will be used for the discussion on Aortic...
Use of the Prodigy Balloon for CTO – “Vascular Disease Management”
Drs. Soundos K. Moualla, and Richard R. Heuser have recently co-authored an important article on the Vascular Disease Management website. We encourage you to read "The Utility of the Prodigy Balloon in Chronic Total Occlusion". Dr. Heuser is the program director of...
Retrograde Crossing Post on “Vascular Disease Management”
Dr. Richard R. Heuser, program director for the upcoming Cardiovascular Disease Management: A Case-Based Approach symposium taking place October 4-5, 2013, has recently posted a must-read article on Vascular Disease Management co-authored by Dr. Ajay Mhatre. To read...
UTHealth/Memorial Hermann first to implant new aortic valve in Houston
Houston Aortic Symposium program director Dr. Hazim J. Safi, and faculty member Anthony L. Estrera are part of the team that will implant the first Sapien heart valve after it's recent FDA approval this month! Join Drs. Safi and David D. McPherson in Houston March 22,...
Recent Comments